Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic Study in Cardiac and Lung Transplantation
NCT00154193Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2004
- Primary completion
- Nov 2007
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine in heart transplant rejection and lung transplant rejection, sponsored by Novartis. Primary endpoints: Average number of treated acute cardiac and lung graft rejection per patient at 12 months and Glomerular Filtration Rate at 12 months. Started Jun 2004; status: completed.
02
Drugs
cyclosporine
03
Conditions
heart transplant rejectionlung transplant rejection
Beyond the preview
Go deeper on NCT00154193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00154193.